Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis

Background. TNF-α inhibitors have shown to be effective in reducing disease activity and improving the quality of life. Due to the high costs associated with acquisition of this treatment, this study was undertaken to evaluate the ICER of TNF-α antagonists (etanercept, adalimumab, and infliximab) in...

Full description

Saved in:
Bibliographic Details
Main Authors: Cynthia Said, Bernard Coleiro, Maurice Zarb Adami, Lilian M. Azzopardi, Anthony Serracino Inglott
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:International Journal of Inflammation
Online Access:http://dx.doi.org/10.1155/2013/581409
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832557013016510464
author Cynthia Said
Bernard Coleiro
Maurice Zarb Adami
Lilian M. Azzopardi
Anthony Serracino Inglott
author_facet Cynthia Said
Bernard Coleiro
Maurice Zarb Adami
Lilian M. Azzopardi
Anthony Serracino Inglott
author_sort Cynthia Said
collection DOAJ
description Background. TNF-α inhibitors have shown to be effective in reducing disease activity and improving the quality of life. Due to the high costs associated with acquisition of this treatment, this study was undertaken to evaluate the ICER of TNF-α antagonists (etanercept, adalimumab, and infliximab) in improving the quality of life. Methods. The HAQ and SF-36 were administered at phases 1, 2, and 3, in order to assess the improvement in the QOL. Suppression of disease activity was assessed through the DAS-28. Results. Statistically significant improvements (P<0.05) were noted for the SF-36 and HAQ after 3 months and for the DAS-28 after 6 months of TNF-α inhibitor therapy. The mean ICER per 10% improvement in the HAQ, DAS-28, and SF-6D were €1976.5, €2086.5, and €2316.4, respectively, following 6 months of TNF-α intervention. Most favorable ICERs were reported from a patient who had to undergo surgical intervention whilst on DMARD therapy. Conclusion. Significant improvement was observed in patients’ quality of life, after a short timeframe of 6 months. Such data is useful information in the light of convincing policy makers, in terms of providing access to the medications to individual patients on national health service schemes.
format Article
id doaj-art-4052a75d1234479495945aeb857fdab7
institution Kabale University
issn 2090-8040
2042-0099
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series International Journal of Inflammation
spelling doaj-art-4052a75d1234479495945aeb857fdab72025-02-03T05:43:50ZengWileyInternational Journal of Inflammation2090-80402042-00992013-01-01201310.1155/2013/581409581409Cost Effectiveness of TNF-α Inhibitors in Rheumatoid ArthritisCynthia Said0Bernard Coleiro1Maurice Zarb Adami2Lilian M. Azzopardi3Anthony Serracino Inglott4Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida MSD 2080, MaltaDepartment of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida MSD 2080, MaltaDepartment of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida MSD 2080, MaltaDepartment of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida MSD 2080, MaltaDepartment of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida MSD 2080, MaltaBackground. TNF-α inhibitors have shown to be effective in reducing disease activity and improving the quality of life. Due to the high costs associated with acquisition of this treatment, this study was undertaken to evaluate the ICER of TNF-α antagonists (etanercept, adalimumab, and infliximab) in improving the quality of life. Methods. The HAQ and SF-36 were administered at phases 1, 2, and 3, in order to assess the improvement in the QOL. Suppression of disease activity was assessed through the DAS-28. Results. Statistically significant improvements (P<0.05) were noted for the SF-36 and HAQ after 3 months and for the DAS-28 after 6 months of TNF-α inhibitor therapy. The mean ICER per 10% improvement in the HAQ, DAS-28, and SF-6D were €1976.5, €2086.5, and €2316.4, respectively, following 6 months of TNF-α intervention. Most favorable ICERs were reported from a patient who had to undergo surgical intervention whilst on DMARD therapy. Conclusion. Significant improvement was observed in patients’ quality of life, after a short timeframe of 6 months. Such data is useful information in the light of convincing policy makers, in terms of providing access to the medications to individual patients on national health service schemes.http://dx.doi.org/10.1155/2013/581409
spellingShingle Cynthia Said
Bernard Coleiro
Maurice Zarb Adami
Lilian M. Azzopardi
Anthony Serracino Inglott
Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
International Journal of Inflammation
title Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
title_full Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
title_fullStr Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
title_full_unstemmed Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
title_short Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
title_sort cost effectiveness of tnf α inhibitors in rheumatoid arthritis
url http://dx.doi.org/10.1155/2013/581409
work_keys_str_mv AT cynthiasaid costeffectivenessoftnfainhibitorsinrheumatoidarthritis
AT bernardcoleiro costeffectivenessoftnfainhibitorsinrheumatoidarthritis
AT mauricezarbadami costeffectivenessoftnfainhibitorsinrheumatoidarthritis
AT lilianmazzopardi costeffectivenessoftnfainhibitorsinrheumatoidarthritis
AT anthonyserracinoinglott costeffectivenessoftnfainhibitorsinrheumatoidarthritis